Pfizer, BioNTech Choose Coronavirus Vaccine Candidate to Advance to Phase 2/3 Trial
Two companies considered to be advanced in their pursuit of a coronavirus vaccine, Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX), have selected one candidate for advancement to a phase 2/3 clinical study. The two companies, which are collaborating on the vaccine effort, said Monday in a joint press release that they have chosen BNT162b2, one of four candidates they were testing.
The selection was made after evaluating data from phase 1/2 clinical trials of all four candidates. Pfizer and BioNTech said they also consulted with the Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research and other regulators on the choice.
Image source: Getty Images.
Source Fool.com
